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OBJECTIVES The aim of the study was to verify the prognostic implications of viability detection using
baseline-nitrate sestamibi imaging in patients with left ventricular (LV) dysfunction due to
chronic coronary artery disease (CAD) submitted to different therapeutic strategies.
BACKGROUND The prognostic meaning of preserved viability in these patients is still debated. Sestamibi is
increasingly used for myocardial perfusion scintigraphy and is being accepted also as viability
tracer, but no data are available about the relationship between viability in sestamibi imaging,
subsequent treatment, and patient’s outcome.
METHODS Follow-up data were collected in 105 CAD patients with LV dysfunction who had undergone
baseline-nitrate sestamibi perfusion imaging for viability assessment and had been later
treated medically (group 1), or submitted to revascularization, which was either complete
(group 2A) or incomplete (group 2B).
RESULTS Eighteen hard events (cardiac death or nonfatal myocardial infarction) were registered during
the follow-up. A significantly worse event-free survival curve was observed in the patients of
group 1 (p , 0.0002) and group 2B (p , 0.03) compared to those of group 2A. Using a Cox
proportional hazard model, the most powerful prognostic predictors of events were the
number of nonrevascularized asynergic segments with viability in sestamibi imaging (p ,
0.003, risk ratio [RR] 5 1.4), and the severity of CAD (p , 0.02, RR 5 1.28).
CONCLUSIONS Viability detection in sestamibi imaging has important prognostic implications in CAD
patients with LV dysfunction. Patients with preserved viability kept on medical therapy or
submitted to incomplete revascularization represent high-risk groups. (J Am Coll Cardiol
2000;36:739–45) © 2000 by the American College of Cardiology
In patients with chronic coronary artery disease (CAD) and
left ventricular (LV) dysfunction, viable myocardium in
asynergic regions subtended by a stenotic vessel may recover
its function when adequate coronary flow is restored (1,2). If
sufficient viable tissue is present, increase in global LV
ejection fraction (EF) and improvement of clinical symp-
toms are usually registered after coronary revascularization
(3–6). Other studies indicate that patients with preserved
viability have a worse prognosis if kept on medical therapy
than if submitted to coronary revascularization (5–16).
Thus, the assessment of myocardial viability is very impor-
tant to identify those who will benefit from a revasculariza-
tion procedure. Various imaging methods are used, such as
positron emission tomography (3), myocardial perfusion
scintigraphy with thallium-201 (4), and low-dose dobut-
amine echocardiography (6). After initial concerns, also
myocardial perfusion imaging with Tc-99m sestamibi (ses-
tamibi), particularly in combination with nitrate adminis-
tration, has been demonstrated to give reliable results in the
detection of viable hibernating myocardium and in the
prediction of postrevascularization recovery (17–21). How-
ever, scanty data are available about the potential prognostic
implications of viability detection using sestamibi. The aim
of this study was to evaluate the outcome of patients with
LV dysfunction due to chronic CAD, taking into account 1)
the presence of viable myocardium in asynergic LV seg-
ments demonstrated using baseline-nitrate sestamibi single-
photon emission computed tomography (SPECT), and 2)
the subsequent therapeutic strategy.
METHODS
Patient selection. Between 1991 and 1997, a total of 115
patients with chronic CAD, reduced global LV function
(LVEF ,50% as assessed by echocardiography or radionu-
clide ventriculography), and severely abnormal regional wall
motion in at least one coronary artery territory, were
subjected in our laboratory to sestamibi imaging for viability
detection. All patients were considered to be possible
candidates for coronary revascularization. None of them had
unstable angina or recent (,2 months) myocardial infarc-
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tion. History of previous myocardial infarction was present
in 90 subjects. Of the 115 patients, 2 were excluded because
they refused coronary angiography, and 8 were lost at
follow-up. Therefore, the study group included 105 patients
(95 men and 10 women, mean age 60.6 6 10.6, range 35 to
83 years). Patients were not randomized for medical treat-
ment or coronary revascularization or, in the latter case, for
percutaneous transluminal coronary angioplasty (PTCA) or
coronary artery bypass grafting (CABG) and complete or
incomplete revascularization. The referring physicians made
the decisions on clinical grounds, taking into account
symptoms severity, response to therapy, coronary anatomy,
patient preferences, and imaging data, including those of
the present study.
Coronary angiography. All 105 patients underwent coro-
nary angiography using the percutaneous transfemoral tech-
nique. Two experienced observers, who were unaware of
patient data, using multiple projections evaluated percent
diameter stenosis. Vessels showing .50% lumen reduction
were considered diseased. The severity of CAD was esti-
mated using an angiographic scoring system (coronary
artery jeopardy score) ranging from 0 (no obstructions
.75%) to 12 (proximal obstructions of all three main
coronary arteries) (22).
Sestamibi single-photon emission computed tomography
(SPECT). The protocol included two separate studies, one
after tracer injection at rest and the other after tracer
administration during nitrate infusion, as previously de-
scribed (18,19). Sestamibi dose was 20 to 25 mCi (740 to
925 MBq) in both instances. Images were collected approx-
imately 1 h later using a single-head, large-field-of-view
tomographic gamma camera equipped with an ultra-high
resolution collimator, and with a 20% window centered on
the 140-keV photopeak of technetium-99m. Sixty projec-
tions of 20 s each were acquired. Image reconstruction was
performed using filtered backprojection, without attenua-
tion or scatter correction, and the slices were realigned along
the heart axis.
Image analysis. Sestamibi SPECT data were analyzed
quantitatively. The short-axis slices from the first with
apical activity, to the last with activity at the base, were used
and their count profiles were generated by computer soft-
ware and plotted onto a two-dimensional volume-weighted
polar map. The polar maps were divided into 13 segments,
which were assigned to the related coronary artery distribu-
tion using an established scheme (19,23), as shown in
Figure 1. Using an automated procedure, segment tracer
activity was calculated as the total of the normalized counts
of the pixels included within the segment divided by the
pixel number. The segment with maximal activity was then
normalized to 100 and the activity of the other segments
was expressed as a percentage of the peak activity segment
(19).
Definition of myocardial viability. The assessment of
viability was restricted to the segments with resting wall
motion abnormality as determined by two-dimensional
echocardiography using a 13-segment model, matching
with the SPECT one (18,19,23). The wall motion of each
segment was scored from 1 (normokinesia) to 4 (dyskinesia)
and segments with score $2 were considered asynergic (24).
The perfusion images were evaluated using our established
interpretation approach, which takes into account the base-
line activity level, the nitrate activity level, and the nitrate-
induced activity changes (19). Asynergic segments were
defined viable if an activity increase greater than 10% was
registered in nitrate SPECT compared to baseline imaging
(19). Conversely, viability was excluded in the case of nitrate-
induced decrease greater than 10%. Finally, in the segments
with a nitrate-induced activity change between 610% of
baseline activity, viability was considered to be present if
activity in nitrate SPECT was $65% (19).
Follow-up data. Patients were followed up by review of
hospital records and by telephone contact with the patient,
relatives, or referring physician. An investigator who was
unaware of sestamibi results collected follow-up data. The
mean follow-up period was 27 6 22 months. The evaluated
events were cardiac death and nonfatal myocardial infarc-
tion.
Abbreviations and Acronyms
ANOVA 5 analysis of variance
CABG 5 coronary artery bypass grafting
CAD 5 coronary artery disease
CCS 5 Canadian Cardiovascular Society
CI 5 confidence interval
EF 5 ejection fraction
LV 5 left ventricular
NYHA 5 New York Heart Association
PTCA 5 percutaneous transluminal coronary
angioplasty
RR 5 risk ratio
SPECT 5 single-photon emission computed
tomography
Figure 1. Diagram of the 13-segment model used for SPECT and
echocardiography data analysis, showing the relation between each seg-
ment and the related coronary artery territory. Areas with vertical lines 5
left anterior descending artery; areas with horizontal lines 5 left circumflex
artery; open areas 5 right coronary artery.
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Statistical analysis. Values are presented as mean value 6
standard deviation (SD). In the case of nominal variables,
the median is indicated as well. Continuous variables were
compared with the one-way analysis of variance (ANOVA)
and nominal variables with the Kruskal-Wallis ANOVA.
The comparisons of proportions were made using either the
Fisher exact test or the chi-square test with Yates’ correction
as appropriate. Survival curves were constructed using the
Kaplan-Meier method and were compared with the log-
rank test. The Cox proportional hazards survival model was
used to identify the independent predictors of patient’s
outcome. The STATISTICA 4.5 software package was
used for all statistical calculations. A probability value of
p , 0.05 was considered statistically significant.
RESULTS
General findings. The leading indication for viability im-
aging was effort or resting dyspnea in 36 patients, stable
angina in the presence of LV dysfunction in eight cases, and
prior myocardial infarction with evidence of LV dysfunction
in 61 patients. Within this last group, 21 patients were
asymptomatic, whereas 40 reported effort chest pain. The
overall mean Canadian Cardiovascular Society (CCS) clas-
sification of angina severity was 1.3 6 0.5 (median 1). The
overall average New York Heart Association (NYHA)
functional class was 1.5 6 0.6 (median 1). The LVEF at the
time of perfusion imaging was 33.9 6 9.2%. A clearly
depressed LV function (LVEF ,40%) was registered in 70
patients. According to coronary angiography, 24 patients
had one-vessel, 37 two-vessel, and 44 three-vessel CAD.
The average coronary artery jeopardy score of the patient
population was 6.3 6 2.6, median 6, and range 2 to 12. The
mean number of asynergic segments per patient was 7.8 6
2.9, median 7, and range 2 to 13.
Sestamibi SPECT. According to sestamibi SPECT, only
six patients did not show any viable asynergic segment. The
remaining 99 patients showed a mean of 4.6 6 2.6 viable
asynergic segments, median 4, range 1 to 13. Taking into
account the distribution of the viable asynergic segments in
the three different coronary territories, all territories with
significant CAD included viable myocardium in 44 patients,
one-third in 4, one-half in 13, and two-thirds in 17 patients.
Figure 2 shows an example of preserved viability in a patient
with three-vessel CAD and severe LV dysfunction.
Patient treatment. Twenty-six patients were kept on med-
ical therapy (group 1), and 79 were submitted to coronary
revascularization (PTCA in 37 cases, CABG in 42 cases)
(group 2). Independently of the adopted technique, the
revascularization procedure involved all vessels with signif-
icant CAD in 55 patients (group 2A), and was incomplete
in the remaining 24 patients (group 2B), involving one-
third stenotic vessels in 5 cases, one-half in 10 cases and
two-thirds in 9 cases. Group 1 showed a significantly higher
NYHA class (1.8 6 0.7, median 2) than did group 2
(1.43 6 0.5, median 1, p , 0.05): no other significant
difference between the two groups was observed in the
variables listed in Table 1, which compares the features of
the patients included in the three different treatment
groups. Group 2B showed a significantly more severe CAD
than did group 1 and also a higher number of diseased
vessels than group 2A. The other statistically significant
difference between groups 2A and 2B was the higher rate of
PTCA versus CABG in the latter group.
Follow-up evaluation. During follow-up, 18 events were
registered. They included 11 sudden deaths, 1 death because
of untreatable congestive heart failure, 3 fatal myocardial
infarctions, and 3 nonfatal myocardial infarctions. The main
demographic, clinical, angiographic and scintigraphic find-
ings of the patients with events versus those without events
are shown in Table 2. The most significant difference
between the two groups was in the number of nonrevascu-
larized asynergic segments with viability in sestamibi
SPECT. The Kaplan-Meier survival curves showed a sig-
Figure 2. Diagram of the coronary artery tree (upper panel) and myocar-
dial perfusion polar map displays (lower panel) of a patient with three-
vessel CAD (coronary artery jeopardy score 5 10) and severe LV
dysfunction (NYHA functional class 2, LVEF 20%). On the baseline
study, large moderate uptake defects are observed in the anterior and
inferior wall, with clear increase in sestamibi activity on the nitrate study.
The patient was refused by the surgeon for technical difficulties in
performing CABG and for the high risk associated with the procedure.
Therefore, the patient underwent successful PTCA on LCX (left circum-
flex artery), and on RCA (right coronary artery), whereas the LAD (left
anterior descending) could not be treated. The patient had regional and
global functional recovery (LVEF 40%), with disappearance of effort
dyspnea, but died because of sudden death seven months after PTCA.
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nificant difference between group 2A and both group 1 (p ,
0.0002) and group 2B (p , 0.03). Conversely, no significant
difference was observed between the survival curves of these
last two groups (Fig. 3).
Determinants of cardiac events. Table 3 lists the variables
found to be independent predictors of cardiac events during
the follow-up according to Cox univariate analysis. In
multivariate analysis using a backward stepwise procedure, a
final model was selected (chi-square 18.8, p , 0.0001)
including as predictive variables 1) the number of viable
asynergic segments not submitted to revascularization (p ,
0.0002, risk ratio [RR] 5 1.4, 95% confidence interval [CI]
5 1.19–1.65) and 2) the coronary artery jeopardy score (p ,
0.02, RR 5 1.28, 95% CI 5 1.05–1.55). As shown in
Figure 4, a significantly worse survival curve was observed in
the patients with more than three viable asynergic segments
not submitted to revascularization compared to those with
one to three nonrevascularized viable segments and to those
with complete revascularization of all viable asynergic seg-
ments.
DISCUSSION
Sestamibi and viability. It has been convincingly shown
that sestamibi can be a valuable viability tracer, if SPECT
imaging with uptake quantification is performed (17,20).
Furthermore, both we and others demonstrated that sesta-
mibi injection during nitrate administration could improve
its accuracy in viability recognition (18,19,21). So far,
however, no data were available about the possible prognosis
implications of viability detection using sestamibi. In our
study, we examined the relationship between viability in
asynergic regions demonstrated using baseline-nitrate ses-
tamibi SPECT and the outcome of CAD patients with LV
dysfunction and treated with different therapeutic strategies.
According to our results, the extent of viable asynergic
myocardium not submitted to revascularization was a pow-
erful predictor of subsequent events.
Comparison with previous studies. This study confirms
previous reports that correlated myocardial viability and
treatment strategy with the prognosis of CAD patients with
LV dysfunction. Using positron emission tomography,
Table 1. Demographic, Clinical, Angiographic and Treatment Data of the Three Patient Groups (see text)
Group 1
(n 5 26)
Group 2A
(n 5 55)
Group 2B
(n 5 24) p Value
Age (yrs) 63.7 6 10.1 59.6 6 10.3 59.5 6 11.4 NS
Male gender 96% 87% 88% NS
Myocardial infarction 85% 87% 83% NS
Angina 38% 51% 42% NS
CCS classification 1.3 6 0.4 [1] 1.2 6 0.5 [1] 1.3 6 0.4 [1] NS
NYHA functional class 1.8 6 0.7 [2] 1.4 6 0.5 [1] 1.5 6 0.6 [1] Gr. 1 vs. 2 , 0.05
Gr. 1 vs. 2a , 0.05
LVEF (%) 31.5 6 10.2 35 6 9 34 6 8.4 NS
Diseased vessels 2 6 0.7 [2] 2.1 6 0.9 [2] 2.5 6 0.5 [3] Gr. 1 vs. 2b , 0.05
Gr. 2a vs. 2b , 0.05
Coronary artery jeopardy score 5.5 6 2.5 [6] 6.5 6 2.9 [6] 7 6 2.1 [7] Gr. 1 vs. 2b , 0.05
Asynergic segments 8 6 3 [8] 7.8 6 3 [7] 8 6 3 [8] NS
Viable asynergic segments 4.8 6 2.4 [5.5] 4.5 6 2.6 [4] 4.7 6 2.9 [4] NS
CABG/PTCA NA 35/20 7/17 , 0.05
Gr. 5 group; n 5 number; NA 5 not applicable; [ ] 5 median; (other abbreviations: see text).
Table 2. Demographic, Clinical, Angiographic and Treatment Data of the Patients With Events Versus Those Without Events
During the Follow-up
Events
(n 5 18)
No Events
(n 5 87) p Value
Age (yrs) 64.3 6 10.2 59.8 6 10.6 NS
Male gender 78% 93% NS
Myocardial infarction 72% 88% NS
Angina 44% 46% NS
CCS angina classification 1.4 6 0.5 [1] 1.2 6 0.4 [1] NS
NYHA functional class 1.8 6 0.5 [2] 1.4 6 0.6 [1] , 0.01
LVEF (%) 29.2 6 7.9 34.9 6 9.2 , 0.03
Diseased vessels (n) 2.3 6 0.7 [2] 2.1 6 0.8 [2] NS
Coronary artery jeopardy score 7.5 6 2.3 [7] 6.1 6 2.7 [6] , 0.05
Asynergic segments 8.7 6 3.6 [9] 7.7 6 2.8 [7] NS
Viable asynergic segments 5.8 6 3.1 [6] 4.4 6 2.5 [4] , 0.05
CABG/PTCA 5/5 37/32 NS
Nonrevascularized viable asynergic segments 3.3 6 3 [2] 1.1 6 2 [0] , 0.001
n 5 number; [ ] 5 median; (other abbreviations: see text).
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Eitzman et al. (7) and DiCarli et al. (10) registered a 50%
and a 41% event rate, respectively, in medically treated
patients with signs of preserved viability. Conversely, both
the patients without viability and those that had been
submitted to coronary revascularization had a clearly better
event-free survival. Other investigators (8,9,11) reported
similar findings. Using rest-redistribution thallium-201
SPECT, Gioia et al. (12) observed among the patients with
viability a significantly worse survival rate (66% vs. 84%) in
the medically than in the surgically treated group, and
Cuocolo et al. (15) demonstrated that the amount of viable
myocardium was the best predictor of cardiac death.
Examining only medically treated patients, Gioia et al.
(13) registered a 74% survival rate in patients without
redistribution versus 42% in those with redistribution, and
Petretta et al. (14) demonstrated that the sum of viable
segments in rest-redistribution thallium-201 SPECT was
significantly higher in the patients with hard events than in
those with soft events or without events. Using low-dose
dobutamine echocardiography and comparing patients kept
on medical therapy with others who underwent coronary
revascularization, Afridi et al. (16) registered a significantly
lower mortality in patients with evidence of viability and
subsequent revascularization than in all other groups.
The role of revascularization completeness. Another ob-
servation of this study was that patients with viable myo-
cardium submitted to an incomplete revascularization pro-
cedure still represent a high-risk group, with an event-free
survival not significantly different from that of medically
treated patients and clearly worse compared to those who
underwent complete revascularization.
Various reports had already demonstrated a better prog-
nosis after complete revascularization in patients submitted
to CABG because of anginal symptoms, particularly if they
had three-vessel CAD and LV dysfunction (25–27). So far,
however, the issue has not been examined in patients in
whom LV dysfunction is the main indication to CABG,
and in such patients the superiority of surgery over medical
therapy is still debated (28). More intricate is the problem of
revascularization completeness using PTCA. Comparative
studies suggest that PTCA may be an attractive alternative
to CABG also in patients with multivessel CAD (29). The
BARI study demonstrated a significant superiority of
CABG over PTCA only in diabetic patients (30). Most
recently, Bourassa et al. (31) reported that nine-year survival
in multivessel CAD patients treated using PTCA was not
compromised by an incomplete revascularization, which
only determined a higher incidence of later CABG. None of
these studies, however, focused on viability, and few data
area viable in anginal patients with depressed LV function.
Holmes et al. (32) suggested that PTCA achieves fairly
good results in these patients. Faxon et al. (33) reported that
incomplete revascularization was related to a worse progno-
sis only if segments with some degree of preserved wall
motion were left untreated. Thus, considering the higher
surgical risk in patients with depressed LV function, incom-
plete revascularization could be considered a reasonable
achievement in many multivessel CAD patients. In this
Figure 3. Kaplan-Meier survival curves of the three patient groups iden-
tified according to treatment (see text).
Figure 4. Kaplan-Meier survival curves of the three patient groups iden-
tified according to the number of viable asynergic segments not submitted
to revascularization.
Table 3. Predictors of Future Cardiac Events According to Univariate Cox Analysis
Variable Chi-square Risk Ratio 95% Confidence Interval p Value
Nonrevascularized viable asynergic segments 12.3 1.34 1.15–1.55 , 0.0005
Completeness of revascularization (%) 8.9 0.98 0.97–0.99 , 0.003
NYHA functional class 6.6 2.78 1.28–6.04 , 0.02
Presence of complete revascularization 6 0.29 0.10–0.83 , 0.02
LVEF 5.9 0.93 0.89–0.98 , 0.02
Age 4.3 1.05 1–1.1 , 0.05
Coronary artery jeopardy score 3.9 1.18 1–1.4 , 0.05
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scenario, the results of our study might be of interest
because they suggest that, similarly to diabetic patients, the
subjects with depressed LV and preserved viability also
constitute a subset of patients who badly tolerate an incom-
plete revascularization procedure.
Study limitations. As for most reports on the same topic,
the principal limitation of the present one is the study
design, which was based on the retrospective evaluation of a
patient cohort submitted to viability assessment, without
randomization of the subsequent treatment. Although many
clinical and instrumental parameters were not significantly
different between the various treatment groups in our series,
other variables could have biased the choice of the thera-
peutic option and, in the case of revascularization, the
decision about the extent of the procedure. In particular, it
cannot be excluded that concern for the high operative risk
had led the referring physician to avoid revascularization or
to limit its extent in patients with more severe CAD and LV
dysfunction, therefore partly explaining the higher event
rate of group 1 and group 2B patients. However, it must be
considered that the already recognized value of viability
detection should have encouraged us to perform a complete
revascularization in patients with a positive imaging study,
and this circumstance would increase the significance of our
data. Another point is the possible concomitant presence of
inducible ischemia as major determinant of adverse out-
come. This problem was not explicitly accounted for in the
study design, and its influence cannot be confidently as-
sessed in our population. It must be considered, however,
that in our hospital the current policy is to send to a viability
study only those patients in whom there is no clear-cut
evidence of inducible ischemia or in whom myocardial
ischemia is difficult to identify—for instance, because of
uninterpretable electrocardiogram or contraindications to
stress testing.
Conclusions and clinical implications. The results of the
present study confirm that detection of viable myocardium
has an adverse prognostic meaning if the related coronary
obstruction is not corrected by revascularization. Of course,
the high hazard of revascularization in patients with LV
dysfunction must be considered, although recent data sug-
gest a relatively lower operative risk in patients with greater
proportion of viable myocardium (34). Once the decision or
revascularization has been taken, however, the completeness
of the procedure should be a straightforward goal. Never-
theless, many different circumstances might justify the
choice of an incomplete approach as an acceptable solution.
With regard to this point, the results of the present study
strongly support the option of always pursuing a complete
procedure, even when confronting higher costs and greater
patient discomfort, and possibly even despite higher risks.
This conclusion, if confirmed by other, possibly prospective,
studies, could have important consequences on the manage-
ment of CAD patients with LV dysfunction.
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